{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T13:09:26Z","timestamp":1773666566816,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003569","name":"Ministry of Food and Drug Safety","doi-asserted-by":"publisher","award":["20173MFDS171"],"award-info":[{"award-number":["20173MFDS171"]}],"id":[{"id":"10.13039\/501100003569","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002551","name":"Seoul National University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002551","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The renal effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors in diverse populations remain under investigation. While randomized controlled trials have shown renoprotective effects of SGLT2 inhibitors, their impact in routine clinical settings and specific populations such as Koreans requires further evaluation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>This study aimed to evaluate the impact of empagliflozin compared to sitagliptin on renal function and related clinical outcomes in patients with type 2 diabetes (T2D) using a target trial emulation approach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study using electronic medical records from a Korean tertiary care hospital between 2018 and 2019. New users of empagliflozin or sitagliptin were identified and matched using propensity scores to control for confounding factors. Primary outcomes included changes in estimated glomerular filtration rate (eGFR) and other renal function markers over time. Secondary outcomes included acute kidney injury, albuminuria, and composite renal events, as well as other clinical parameters. A modified intention-to-treat analysis was performed, with follow-up up to 13\u00a0months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      After matching, 219 T2D patients were identified in each group. Empagliflozin was associated with a slower decline in eGFR compared to sitagliptin (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). Serum phosphorus levels increased more with empagliflozin (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). Empagliflozin showed a non-significant trend toward lower risk of composite renal outcomes (hazard ratio [HR] 0.78; 95% confidence interval [CI], 0.50\u20131.22). Significant increases in weight loss (HR 2.95; 95% CI, 2.01\u20134.33) and urination frequency (HR 4.05; 95% CI, 1.14\u201314.34) were observed with empagliflozin. Serum uric acid levels decreased more in the empagliflozin group (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This real-world study suggests that empagliflozin may offer renoprotective benefits compared to sitagliptin in T2D patients. However, the increased serum phosphorus levels warrant careful monitoring. These findings provide valuable insights for clinical decision-making in managing T2D patients at risk of renal complications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11096-025-02024-9","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T11:03:40Z","timestamp":1761217420000},"page":"569-579","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The effect of empagliflozin on renal outcomes compared to sitagliptin with type 2 diabetes: target trial emulation using electronic medical records"],"prefix":"10.1007","volume":"48","author":[{"given":"Min Ju","family":"Kang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyun Kyung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minoh","family":"Ko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ha Young","family":"Jang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In-Wha","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung Mi","family":"Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,23]]},"reference":[{"issue":"10","key":"2024_CR1","doi-asserted-by":"publisher","first-page":"2864","DOI":"10.2337\/dc14-1296","volume":"37","author":"KR Tuttle","year":"2014","unstructured":"Tuttle KR, Bakris GL, Bilous RW, et al. Diabetic kidney disease: a report from an ADA consensus conference. Diabetes Care. 2014;37(10):2864\u201383. https:\/\/doi.org\/10.2337\/dc14-1296.","journal-title":"Diabetes Care"},{"issue":"4","key":"2024_CR2","doi-asserted-by":"publisher","first-page":"543","DOI":"10.4093\/dmj.2022.0209","volume":"46","author":"NH Kim","year":"2022","unstructured":"Kim NH, Kim NH. Renoprotective mechanism of Sodium-Glucose cotransporter 2 inhibitors: focusing on renal hemodynamics. Diabetes Metab J. 2022;46(4):543\u201351. https:\/\/doi.org\/10.4093\/dmj.2022.0209.","journal-title":"Diabetes Metab J"},{"issue":"8","key":"2024_CR3","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1111\/j.1742-1241.2008.01829.x","volume":"62","author":"SA Jabbour","year":"2008","unstructured":"Jabbour SA, Goldstein BJ. Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes. Int J Clin Pract. 2008;62(8):1279\u201384. https:\/\/doi.org\/10.1111\/j.1742-1241.2008.01829.x.","journal-title":"Int J Clin Pract"},{"issue":"22","key":"2024_CR4","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1504720.","journal-title":"N Engl J Med"},{"key":"2024_CR5","unstructured":"Jardiance (empagliflozin) [package insert]. U.S. Food and Drug Administration. 2016. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/204629s008lbl.pdf. Accessed 02 Dec 2021."},{"key":"2024_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2024.04.011","author":"D Edmonston","year":"2024","unstructured":"Edmonston D, Mulder H, Lydon E, et al. Kidney and cardiovascular effectiveness of empagliflozin compared with dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes. Am J Cardiol. 2024. https:\/\/doi.org\/10.1016\/j.amjcard.2024.04.011.","journal-title":"Am J Cardiol"},{"issue":"4","key":"2024_CR7","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1111\/dom.15429","volume":"26","author":"C Rebordosa","year":"2024","unstructured":"Rebordosa C, Thomsen RW, Tave AK, et al. Liver, renal, genitourinary and diabetic ketoacidosis risks among new users of empagliflozin versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: post-authorization safety study based on multinational cohorts. Diabetes Obes Metab. 2024;26(4):1291\u2013304. https:\/\/doi.org\/10.1111\/dom.15429.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"2024_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2022.101418","volume":"49","author":"A Karasik","year":"2023","unstructured":"Karasik A, Lanzinger S, Chia-Hui Tan E, et al. Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study. Diabetes Metab. 2023;49(2):101418. https:\/\/doi.org\/10.1016\/j.diabet.2022.101418.","journal-title":"Diabetes Metab"},{"key":"2024_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.781379","volume":"12","author":"YT Lee","year":"2021","unstructured":"Lee YT, Hsu CN, Fu CM, et al. Comparison of adverse kidney outcomes with Empagliflozin and Linagliptin use in patients with type 2 diabetic patients in a real-world setting. Front Pharmacol. 2021;12:781379. https:\/\/doi.org\/10.3389\/fphar.2021.781379.","journal-title":"Front Pharmacol"},{"issue":"2","key":"2024_CR10","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/dom.14239","volume":"23","author":"ES Koh","year":"2021","unstructured":"Koh ES, Han K, Nam YS, et al. Renal outcomes and all-cause death associated with sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL 3 Korea). Diabetes Obes Metab. 2021;23(2):455\u201366. https:\/\/doi.org\/10.1111\/dom.14239.","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"2024_CR11","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.2337\/dc20-1890","volume":"43","author":"Y Xie","year":"2020","unstructured":"Xie Y, Bowe B, Gibson AK, et al. Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of kidney outcomes: emulation of a target trial using health care databases. Diabetes Care. 2020;43(11):2859\u201369. https:\/\/doi.org\/10.2337\/dc20-1890.","journal-title":"Diabetes Care"},{"issue":"36","key":"2024_CR12","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2021.36.e230","volume":"36","author":"KA Lee","year":"2021","unstructured":"Lee KA, Jin HY, Kim YJ, et al. Treatment patterns of type 2 diabetes assessed using a common data model based on electronic health records of 2000\u20132019. J Korean Med Sci. 2021;36(36):e230. https:\/\/doi.org\/10.3346\/jkms.2021.36.e230.","journal-title":"J Korean Med Sci"},{"key":"2024_CR13","unstructured":"Notification of label change according to drug re-examination result [empagliflozin and metformin hydrochloride ingredient formulation (combination drug, oral drug)] 2021. https:\/\/nedrug.mfds.go.kr\/pbp\/CCBAQ03\/getItem?totalPages=397&limit=10&page=3&bbsYn=Y&orderNo=&bbscttNo=4639. Accessed 02 Dec 2021."},{"issue":"3","key":"2024_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2023.100783","volume":"6","author":"S Hadjadj","year":"2024","unstructured":"Hadjadj S, Cooper ME, Steubl D, et al. Empagliflozin and rapid kidney function decline incidence in type 2 diabetes: an exploratory analysis from the EMPA-REG OUTCOME trial. Kidney Med. 2024;6(3):100783. https:\/\/doi.org\/10.1016\/j.xkme.2023.100783.","journal-title":"Kidney Med"},{"issue":"1","key":"2024_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/s2213-8587(19)30384-5","volume":"8","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Karasik A, Thuresson M, et al. Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study. Lancet Diabetes Endocrinol. 2020;8(1):27\u201335. https:\/\/doi.org\/10.1016\/s2213-8587(19)30384-5.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"2024_CR16","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1093\/ckj\/sfac044","volume":"15","author":"AYL Liu","year":"2022","unstructured":"Liu AYL, Low S, Yeoh E, et al. A real-world study on SGLT2 inhibitors and diabetic kidney disease progression. Clin Kidney J. 2022;15(7):1403\u201314. https:\/\/doi.org\/10.1093\/ckj\/sfac044.","journal-title":"Clin Kidney J"},{"key":"2024_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00820","volume":"10","author":"YH Lin","year":"2019","unstructured":"Lin YH, Huang YY, Hsieh SH, et al. Renal and glucose-lowering effects of Empagliflozin and Dapagliflozin in different chronic kidney disease stages. Front Endocrinol (Lausanne). 2019;10:820. https:\/\/doi.org\/10.3389\/fendo.2019.00820.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2024_CR18","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15623","author":"A Nakhleh","year":"2024","unstructured":"Nakhleh A, Abdul-Ghani M, Gazit S, et al. Real-world effectiveness of sodium-glucose cotransporter-2 inhibitors on the progression of chronic kidney disease in patients without diabetes, with and without albuminuria. Diabetes Obes Metab. 2024. https:\/\/doi.org\/10.1111\/dom.15623.","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"2024_CR19","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1093\/aje\/kwv254","volume":"183","author":"MA Hern\u00e1n","year":"2016","unstructured":"Hern\u00e1n MA, Robins JM. Using big data to emulate a target trial when a randomized trial is not available. Am J Epidemiol. 2016;183(8):758\u201364. https:\/\/doi.org\/10.1093\/aje\/kwv254.","journal-title":"Am J Epidemiol"},{"issue":"4","key":"2024_CR20","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1515920","volume":"375","author":"C Wanner","year":"2016","unstructured":"Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1515920.","journal-title":"N Engl J Med"},{"issue":"15","key":"2024_CR21","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413\u201324. https:\/\/doi.org\/10.1056\/NEJMoa2022190.","journal-title":"N Engl J Med"},{"issue":"9","key":"2024_CR22","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1007\/s00125-016-4008-2","volume":"59","author":"D Cherney","year":"2016","unstructured":"Cherney D, Lund SS, Perkins BA, et al. The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes. Diabetologia. 2016;59(9):1860\u201370. https:\/\/doi.org\/10.1007\/s00125-016-4008-2.","journal-title":"Diabetologia"},{"issue":"3","key":"2024_CR23","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1111\/jdi.12971","volume":"10","author":"T Kadowaki","year":"2019","unstructured":"Kadowaki T, Nangaku M, Hantel S, et al. Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: results from the EMPA-REG OUTCOME(\u00ae) trial. J Diabetes Investig. 2019;10(3):760\u201370. https:\/\/doi.org\/10.1111\/jdi.12971.","journal-title":"J Diabetes Investig"},{"issue":"3","key":"2024_CR24","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s40264-017-0602-6","volume":"41","author":"A Szalat","year":"2018","unstructured":"Szalat A, Perlman A, Muszkat M, et al. Can SGLT2 inhibitors cause acute renal failure? Plausible role for altered glomerular hemodynamics and medullary hypoxia. Drug Saf. 2018;41(3):239\u201352. https:\/\/doi.org\/10.1007\/s40264-017-0602-6.","journal-title":"Drug Saf"},{"issue":"2","key":"2024_CR25","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s10741-020-10024-2","volume":"26","author":"D Margonato","year":"2021","unstructured":"Margonato D, Galati G, Mazzetti S, et al. Renal protection: a leading mechanism for cardiovascular benefit in patients treated with SGLT2 inhibitors. Heart Fail Rev. 2021;26(2):337\u201345. https:\/\/doi.org\/10.1007\/s10741-020-10024-2.","journal-title":"Heart Fail Rev"},{"issue":"2","key":"2024_CR26","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1053\/j.ajkd.2020.04.016","volume":"77","author":"M Packer","year":"2021","unstructured":"Packer M. Mechanisms leading to differential Hypoxia-Inducible factor signaling in the diabetic kidney: modulation by SGLT2 inhibitors and hypoxia mimetics. Am J Kidney Dis. 2021;77(2):280\u20136. https:\/\/doi.org\/10.1053\/j.ajkd.2020.04.016.","journal-title":"Am J Kidney Dis"},{"key":"2024_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.bonr.2022.101175","volume":"16","author":"M Rau","year":"2022","unstructured":"Rau M, Thiele K, Hartmann NK, et al. Effects of empagliflozin on markers of calcium and phosphate homeostasis in patients with type 2 diabetes - Data from a randomized, placebo-controlled study. Bone Rep. 2022;16:101175. https:\/\/doi.org\/10.1016\/j.bonr.2022.101175.","journal-title":"Bone Rep"},{"issue":"1","key":"2024_CR28","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/s2213-8587(14)70227-x","volume":"3","author":"SI Taylor","year":"2015","unstructured":"Taylor SI, Blau JE, Rother KI. Possible adverse effects of SGLT2 inhibitors on bone. Lancet Diabetes Endocrinol. 2015;3(1):8\u201310. https:\/\/doi.org\/10.1016\/s2213-8587(14)70227-x.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"2024_CR29","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41581-018-0028-0","volume":"14","author":"JE Blau","year":"2018","unstructured":"Blau JE, Taylor SI. Adverse effects of SGLT2 inhibitors on bone health. Nat Rev Nephrol. 2018;14(8):473\u20134. https:\/\/doi.org\/10.1038\/s41581-018-0028-0.","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"2024_CR30","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/dom.14559","volume":"24","author":"JP Ferreira","year":"2022","unstructured":"Ferreira JP, Inzucchi SE, Mattheus M, et al. Empagliflozin and uric acid metabolism in diabetes: a post hoc analysis of the EMPA-REG outcome trial. Diabetes Obes Metab. 2022;24(1):135\u201341. https:\/\/doi.org\/10.1111\/dom.14559.","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"2024_CR31","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.2337\/dc13-2105","volume":"37","author":"HU H\u00e4ring","year":"2014","unstructured":"H\u00e4ring HU, Merker L, Seewaldt-Becker E, et al. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care. 2014;37(6):1650\u20139. https:\/\/doi.org\/10.2337\/dc13-2105.","journal-title":"Diabetes Care"},{"issue":"2","key":"2024_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/antiox10020246","volume":"10","author":"D Kawanami","year":"2021","unstructured":"Kawanami D, Takashi Y, Takahashi H, et al. Renoprotective effects of DPP-4 inhibitors. Antioxidants. 2021;10(2):246. https:\/\/doi.org\/10.3390\/antiox10020246.","journal-title":"Antioxidants"},{"issue":"9","key":"2024_CR33","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.2337\/dc15-0355","volume":"38","author":"G Ferrannini","year":"2015","unstructured":"Ferrannini G, Hach T, Crowe S, et al. Energy balance after Sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015;38(9):1730\u20135. https:\/\/doi.org\/10.2337\/dc15-0355.","journal-title":"Diabetes Care"},{"issue":"2","key":"2024_CR34","doi-asserted-by":"publisher","first-page":"74","DOI":"10.4093\/jkd.2019.20.2.74","volume":"20","author":"K-S Kim","year":"2019","unstructured":"Kim K-S. Sodium-glucose cotransporter 2 inhibitors: mechanisms of action and various effects. J Korean Diabetes. 2019;20(2):74\u201380.","journal-title":"J Korean Diabetes"},{"key":"2024_CR35","doi-asserted-by":"publisher","unstructured":"Masuda T, Muto S, Fukuda K et al. Osmotic diuresis by SGLT2 inhibition stimulates vasopressin-induced water reabsorption to maintain body fluid volume. Physiol Rep. 2020;8(2):e14360. https:\/\/doi.org\/10.14814\/phy2.14360.","DOI":"10.14814\/phy2.14360"},{"issue":"1","key":"2024_CR36","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.1038\/s41598-017-02895-7","volume":"7","author":"BM Ayoub","year":"2017","unstructured":"Ayoub BM, Mowaka S, Elzanfaly ES, et al. Pharmacokinetic evaluation of Empagliflozin in healthy Egyptian volunteers using LC-MS\/MS and comparison with other ethnic populations. Sci Rep. 2017;7(1):2583. https:\/\/doi.org\/10.1038\/s41598-017-02895-7.","journal-title":"Sci Rep"},{"key":"2024_CR37","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-025-01950-y","author":"Q Hu","year":"2025","unstructured":"Hu Q, Yang S, Zhang B, et al. Effects of sodium-glucose cotransporter-2 inhibitors on serum urate levels and gout in patients with and without type 2 diabetes: a systematic review and network meta-analysis. Int J Clin Pharm. 2025. https:\/\/doi.org\/10.1007\/s11096-025-01950-y.","journal-title":"Int J Clin Pharm"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-025-02024-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-025-02024-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-025-02024-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T12:05:16Z","timestamp":1773662716000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-025-02024-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,23]]},"references-count":37,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["2024"],"URL":"https:\/\/doi.org\/10.1007\/s11096-025-02024-9","relation":{},"ISSN":["2210-7711"],"issn-type":[{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,23]]},"assertion":[{"value":"12 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}},{"value":"This study was approved by the Institutional Review Board of Seoul National University Hospital (IRB No. 2106\u2013016-1224, approved on 6 July 2021) and adhered to the Declaration of Helsinki. The requirement for informed consent was waived by the Institutional Review Board because all personally identifiable information had been removed in compliance with relevant guidelines and regulations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}